Table of Contents
EXECUTIVE SUMMARY
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
Global Generics
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Generics in Asia-Pacific
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Generics in Europe
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Generics in France
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Germany
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Australia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Brazil
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in China
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in India
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Indonesia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Italy
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Japan
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Mexico
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The Netherlands
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in North America
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Generics in Russia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Scandinavia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Generics in Singapore
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in South Africa
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in South Korea
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Spain
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Turkey
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United Kingdom
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

List of Tables
Table 1: Global generics market value: $ billion, 2012–16
Table 2: Global generics market volume: % of total pharma volume, 2012–16
Table 3: Global generics market geography segmentation: $ billion, 2016
Table 4: Global generics market value forecast: $ billion, 2016–21
Table 5: Global generics market volume forecast: % of total pharma volume, 2016–21
Table 6: Asia-Pacific generics market value: $ billion, 2012–16
Table 7: Asia–Pacific generics market volume: % of total pharma volume, 2012–16
Table 8: Asia–Pacific generics market geography segmentation: $ billion, 2016
Table 9: Asia-Pacific generics market value forecast: $ billion, 2016–21
Table 10: Asia–Pacific generics market volume forecast: % of total pharma volume, 2016–21
Table 11: Europe generics market value: $ billion, 2012–16
Table 12: Europe generics market volume: % of total pharma volume, 2012–16
Table 13: Europe generics market geography segmentation: $ billion, 2016
Table 14: Europe generics market value forecast: $ billion, 2016–21
Table 15: Europe generics market volume forecast: % of total pharma volume, 2016–21
Table 16: France generics market value: $ billion, 2012–16
Table 17: France generics market volume: % of total pharma volume, 2012–16
Table 18: France generics market geography segmentation: $ billion, 2016
Table 19: France generics market value forecast: $ billion, 2016–21
Table 20: France generics market volume forecast: % of total pharma volume, 2016–21
Table 21: France size of population (million), 2012–16
Table 22: France gdp (constant 2005 prices, $ billion), 2012–16
Table 23: France gdp (current prices, $ billion), 2012–16
Table 24: France inflation, 2012–16
Table 25: France consumer price index (absolute), 2012–16
Table 26: France exchange rate, 2012–16
Table 27: Germany generics market value: $ billion, 2012–16
Table 28: Germany generics market volume: % of total pharma volume, 2012–16
Table 29: Germany generics market geography segmentation: $ billion, 2016
Table 30: Germany generics market value forecast: $ billion, 2016–21
Table 31: Germany generics market volume forecast: % of total pharma volume, 2016–21
Table 32: Germany size of population (million), 2012–16
Table 33: Germany gdp (constant 2005 prices, $ billion), 2012–16
Table 34: Germany gdp (current prices, $ billion), 2012–16
Table 35: Germany inflation, 2012–16
Table 36: Germany consumer price index (absolute), 2012–16
Table 37: Germany exchange rate, 2012–16
Table 38: Australia generics market value: $ billion, 2012–16
Table 39: Australia generics market volume: % of total pharma volume, 2012–16
Table 40: Australia generics market geography segmentation: $ billion, 2016
Table 41: Australia generics market value forecast: $ billion, 2016–21
Table 42: Australia generics market volume forecast: % of total pharma volume, 2016–21
Table 43: Australia size of population (million), 2012–16
Table 44: Australia gdp (constant 2005 prices, $ billion), 2012–16
Table 45: Australia gdp (current prices, $ billion), 2012–16
Table 46: Australia inflation, 2012–16
Table 47: Australia consumer price index (absolute), 2012–16
Table 48: Australia exchange rate, 2012–16
Table 49: Brazil generics market value: $ billion, 2012–16
Table 50: Brazil generics market volume: % of total pharma volume, 2012–16
Table 51: Brazil generics market geography segmentation: $ billion, 2016
Table 52: Brazil generics market value forecast: $ billion, 2016–21
Table 53: Brazil generics market volume forecast: % of total pharma volume, 2016–21
Table 54: Brazil size of population (million), 2012–16
Table 55: Brazil gdp (constant 2005 prices, $ billion), 2012–16
Table 56: Brazil gdp (current prices, $ billion), 2012–16
Table 57: Brazil inflation, 2012–16
Table 58: Brazil consumer price index (absolute), 2012–16
Table 59: Brazil exchange rate, 2012–16
Table 60: Canada generics market value: $ billion, 2012–16
Table 61: Canada generics market volume: % of total pharma volume, 2012–16
Table 62: Canada generics market geography segmentation: $ billion, 2016
Table 63: Canada generics market value forecast: $ billion, 2016–21
Table 64: Canada generics market volume forecast: % of total pharma volume, 2016–21
Table 65: Canada size of population (million), 2012–16
Table 66: Canada gdp (constant 2005 prices, $ billion), 2012–16
Table 67: Canada gdp (current prices, $ billion), 2012–16
Table 68: Canada inflation, 2012–16
Table 69: Canada consumer price index (absolute), 2012–16
Table 70: Canada exchange rate, 2012–16
Table 71: China generics market value: $ billion, 2012–16
Table 72: China generics market volume: % of total pharma volume, 2012–16
Table 73: China generics market geography segmentation: $ billion, 2016
Table 74: China generics market value forecast: $ billion, 2016–21
Table 75: China generics market volume forecast: % of total pharma volume, 2016–21
Table 76: China size of population (million), 2012–16
Table 77: China gdp (constant 2005 prices, $ billion), 2012–16
Table 78: China gdp (current prices, $ billion), 2012–16
Table 79: China inflation, 2012–16
Table 80: China consumer price index (absolute), 2012–16
Table 81: China exchange rate, 2012–16
Table 82: India generics market value: $ billion, 2012–16
Table 83: India generics market volume: % of total pharma volume, 2012–16
Table 84: India generics market geography segmentation: $ billion, 2016
Table 85: India generics market value forecast: $ billion, 2016–21
Table 86: India generics market volume forecast: % of total pharma volume, 2016–21
Table 87: India size of population (million), 2012–16
Table 88: India gdp (constant 2005 prices, $ billion), 2012–16
Table 89: India gdp (current prices, $ billion), 2012–16
Table 90: India inflation, 2012–16
Table 91: India consumer price index (absolute), 2012–16
Table 92: India exchange rate, 2012–16
Table 93: Indonesia generics market value: $ billion, 2012–16
Table 94: Indonesia generics market volume: % of total pharma volume, 2012–16
Table 95: Indonesia generics market geography segmentation: $ billion, 2016
Table 96: Indonesia generics market value forecast: $ billion, 2016–21
Table 97: Indonesia generics market volume forecast: % of total pharma volume, 2016–21
Table 98: Indonesia size of population (million), 2012–16
Table 99: Indonesia gdp (constant 2005 prices, $ billion), 2012–16
Table 100: Indonesia gdp (current prices, $ billion), 2012–16
Table 101: Indonesia inflation, 2012–16
Table 102: Indonesia consumer price index (absolute), 2012–16
Table 103: Indonesia exchange rate, 2012–16
Table 104: Italy generics market value: $ billion, 2012–16
Table 105: Italy generics market volume: % of total pharma volume, 2012–16
Table 106: Italy generics market geography segmentation: $ billion, 2016
Table 107: Italy generics market value forecast: $ billion, 2016–21
Table 108: Italy generics market volume forecast: % of total pharma volume, 2016–21
Table 109: Italy size of population (million), 2012–16
Table 110: Italy gdp (constant 2005 prices, $ billion), 2012–16
Table 111: Italy gdp (current prices, $ billion), 2012–16
Table 112: Italy inflation, 2012–16
Table 113: Italy consumer price index (absolute), 2012–16
Table 114: Italy exchange rate, 2012–16
Table 115: Japan generics market value: $ billion, 2012–16
Table 116: Japan generics market volume: % of total pharma volume, 2012–16
Table 117: Japan generics market geography segmentation: $ billion, 2016
Table 118: Japan generics market value forecast: $ billion, 2016–21
Table 119: Japan generics market volume forecast: % of total pharma volume, 2016–21
Table 120: Japan size of population (million), 2012–16
Table 121: Japan gdp (constant 2005 prices, $ billion), 2012–16
Table 122: Japan gdp (current prices, $ billion), 2012–16
Table 123: Japan inflation, 2012–16
Table 124: Japan consumer price index (absolute), 2012–16
Table 125: Japan exchange rate, 2012–16
Table 126: Mexico generics market value: $ billion, 2012–16
Table 127: Mexico generics market volume: % of total pharma volume, 2012–16
Table 128: Mexico generics market geography segmentation: $ billion, 2016
Table 129: Mexico generics market value forecast: $ billion, 2016–21
Table 130: Mexico generics market volume forecast: % of total pharma volume, 2016–21
Table 131: Mexico size of population (million), 2012–16
Table 132: Mexico gdp (constant 2005 prices, $ billion), 2012–16
Table 133: Mexico gdp (current prices, $ billion), 2012–16
Table 134: Mexico inflation, 2012–16
Table 135: Mexico consumer price index (absolute), 2012–16
Table 136: Mexico exchange rate, 2012–16
Table 137: Netherlands generics market value: $ billion, 2012–16
Table 138: Netherlands generics market volume: % of total pharma volume, 2012–16
Table 139: Netherlands generics market geography segmentation: $ billion, 2016
Table 140: Netherlands generics market value forecast: $ billion, 2016–21
Table 141: Netherlands generics market volume forecast: % of total pharma volume, 2016–21
Table 142: Netherlands size of population (million), 2012–16
Table 143: Netherlands gdp (constant 2005 prices, $ billion), 2012–16
Table 144: Netherlands gdp (current prices, $ billion), 2012–16
Table 145: Netherlands inflation, 2012–16
Table 146: Netherlands consumer price index (absolute), 2012–16
Table 147: Netherlands exchange rate, 2012–16
Table 148: North America generics market value: $ billion, 2012–16
Table 149: North America generics market volume: % of total pharma volume, 2012–16
Table 150: North America generics market geography segmentation: $ billion, 2016
Table 151: North America generics market value forecast: $ billion, 2016–21
Table 152: North America generics market volume forecast: % of total pharma volume, 2016–21
Table 153: Russia generics market value: $ billion, 2012–16
Table 154: Russia generics market volume: % of total pharma volume, 2012–16
Table 155: Russia generics market geography segmentation: $ billion, 2016
Table 156: Russia generics market value forecast: $ billion, 2016–21
Table 157: Russia generics market volume forecast: % of total pharma volume, 2016–21
Table 158: Russia size of population (million), 2012–16
Table 159: Russia gdp (constant 2005 prices, $ billion), 2012–16
Table 160: Russia gdp (current prices, $ billion), 2012–16
Table 161: Russia inflation, 2012–16
Table 162: Russia consumer price index (absolute), 2012–16
Table 163: Russia exchange rate, 2012–16
Table 164: Scandinavia generics market value: $ billion, 2012–16
Table 165: Scandinavia generics market volume: % of total pharma volume, 2012–16
Table 166: Scandinavia generics market geography segmentation: $ billion, 2016
Table 167: Scandinavia generics market value forecast: $ billion, 2016–21
Table 168: Scandinavia generics market volume forecast: % of total pharma volume, 2016–21
Table 169: Singapore generics market value: $ billion, 2012–16
Table 170: Singapore generics market volume: % of total pharma volume, 2012–16
Table 171: Singapore generics market geography segmentation: $ billion, 2016
Table 172: Singapore generics market value forecast: $ billion, 2016–21
Table 173: Singapore generics market volume forecast: % of total pharma volume, 2016–21
Table 174: Singapore size of population (million), 2012–16
Table 175: Singapore gdp (constant 2005 prices, $ billion), 2012–16
Table 176: Singapore gdp (current prices, $ billion), 2012–16
Table 177: Singapore inflation, 2012–16
Table 178: Singapore consumer price index (absolute), 2012–16
Table 179: Singapore exchange rate, 2012–16
Table 180: South Africa generics market value: $ billion, 2012–16
Table 181: South Africa generics market volume: % of total pharma volume, 2012–16
Table 182: South Africa generics market geography segmentation: $ billion, 2016
Table 183: South Africa generics market value forecast: $ billion, 2016–21
Table 184: South Africa generics market volume forecast: % of total pharma volume, 2016–21
Table 185: South Africa size of population (million), 2012–16
Table 186: South Africa gdp (constant 2005 prices, $ billion), 2012–16
Table 187: South Africa gdp (current prices, $ billion), 2012–16
Table 188: South Africa inflation, 2012–16
Table 189: South Africa consumer price index (absolute), 2012–16
Table 190: South Africa exchange rate, 2012–16
Table 191: South Korea generics market value: $ billion, 2012–16
Table 192: South Korea generics market volume: % of total pharma volume, 2012–16
Table 193: South Korea generics market geography segmentation: $ billion, 2016
Table 194: South Korea generics market value forecast: $ billion, 2016–21
Table 195: South Korea generics market volume forecast: % of total pharma volume, 2016–21
Table 196: South Korea size of population (million), 2012–16
Table 197: South Korea gdp (constant 2005 prices, $ billion), 2012–16
Table 198: South Korea gdp (current prices, $ billion), 2012–16
Table 199: South Korea inflation, 2012–16
Table 200: South Korea consumer price index (absolute), 2012–16
Table 201: South Korea exchange rate, 2012–16
Table 202: Spain generics market value: $ billion, 2012–16
Table 203: Spain generics market volume: % of total pharma volume, 2012–16
Table 204: Spain generics market geography segmentation: $ billion, 2016
Table 205: Spain generics market value forecast: $ billion, 2016–21
Table 206: Spain generics market volume forecast: % of total pharma volume, 2016–21
Table 207: Spain size of population (million), 2012–16
Table 208: Spain gdp (constant 2005 prices, $ billion), 2012–16
Table 209: Spain gdp (current prices, $ billion), 2012–16
Table 210: Spain inflation, 2012–16
Table 211: Spain consumer price index (absolute), 2012–16
Table 212: Spain exchange rate, 2012–16
Table 213: Turkey generics market value: $ billion, 2012–16
Table 214: Turkey generics market volume: % of total pharma volume, 2012–16
Table 215: Turkey generics market geography segmentation: $ billion, 2016
Table 216: Turkey generics market value forecast: $ billion, 2016–21
Table 217: Turkey generics market volume forecast: % of total pharma volume, 2016–21
Table 218: Turkey size of population (million), 2012–16
Table 219: Turkey gdp (constant 2005 prices, $ billion), 2012–16
Table 220: Turkey gdp (current prices, $ billion), 2012–16
Table 221: Turkey inflation, 2012–16
Table 222: Turkey consumer price index (absolute), 2012–16
Table 223: Turkey exchange rate, 2012–16
Table 224: United Kingdom generics market value: $ billion, 2012–16
Table 225: United Kingdom generics market volume: % of total pharma volume, 2012–16
Table 226: United Kingdom generics market geography segmentation: $ billion, 2016
Table 227: United Kingdom generics market value forecast: $ billion, 2016–21
Table 228: United Kingdom generics market volume forecast: % of total pharma volume, 2016–21
Table 229: United Kingdom size of population (million), 2012–16
Table 230: United Kingdom gdp (constant 2005 prices, $ billion), 2012–16
Table 231: United Kingdom gdp (current prices, $ billion), 2012–16
Table 232: United Kingdom inflation, 2012–16
Table 233: United Kingdom consumer price index (absolute), 2012–16
Table 234: United Kingdom exchange rate, 2012–16
Table 235: United States generics market value: $ billion, 2012–16
Table 236: United States generics market volume: % of total pharma volume, 2012–16
Table 237: United States generics market geography segmentation: $ billion, 2016
Table 238: United States generics market value forecast: $ billion, 2016–21
Table 239: United States generics market volume forecast: % of total pharma volume, 2016–21
Table 240: United States size of population (million), 2012–16
Table 241: United States gdp (constant 2005 prices, $ billion), 2012–16
Table 242: United States gdp (current prices, $ billion), 2012–16
Table 243: United States inflation, 2012–16
Table 244: United States consumer price index (absolute), 2012–16
Table 245: United States exchange rate, 2012–15
Table 246: Allergan plc: key facts
Table 247: Allergan plc: key financials ($)
Table 248: Allergan plc: key financial ratios
Table 249: Mylan Inc.: key facts
Table 250: Mylan Inc.: key financials ($)
Table 251: Mylan Inc.: key financial ratios
Table 252: Sandoz International GmbH: key facts
Table 253: Teva Pharmaceutical Industries Limited: key facts
Table 254: Teva Pharmaceutical Industries Limited: key financials ($)
Table 255: Teva Pharmaceutical Industries Limited: key financial ratios
Table 256: Sun Pharmaceutical Industries Ltd.: key facts
Table 257: Sun Pharmaceutical Industries Ltd.: key financials ($)
Table 258: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)
Table 259: Sun Pharmaceutical Industries Ltd.: key financial ratios
Table 260: Sanofi SA: key facts
Table 261: Sanofi SA: key financials ($)
Table 262: Sanofi SA: key financials (€)
Table 263: Sanofi SA: key financial ratios
Table 264: Les Laboratoires Servier: key facts
Table 265: STADA Arzneimittel AG: key facts
Table 266: STADA Arzneimittel AG: key financials ($)
Table 267: STADA Arzneimittel AG: key financials (€)
Table 268: STADA Arzneimittel AG: key financial ratios
Table 269: Aspen Pharmacare Holdings Ltd: key facts
Table 270: Aspen Pharmacare Holdings Ltd: key financials ($)
Table 271: Aspen Pharmacare Holdings Ltd: key financials (ZAR)
Table 272: Aspen Pharmacare Holdings Ltd: key financial ratios
Table 273: O Ache Laboratorios Farmaceuticos S.A.: key facts
Table 274: EMS Sigma Pharma: key facts
Table 275: Eurofarma Laboratórios S.A.: key facts
Table 276: Apotex, Inc.: key facts
Table 277: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
Table 278: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
Table 279: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
Table 280: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
Table 281: Aurobindo Pharma Limited: key facts
Table 282: Aurobindo Pharma Limited: key financials ($)
Table 283: Aurobindo Pharma Limited: key financials (Rs.)
Table 284: Aurobindo Pharma Limited: key financial ratios
Table 285: Cipla Limited: key facts
Table 286: Cipla Limited: key financials ($)
Table 287: Cipla Limited: key financials (Rs.)
Table 288: Cipla Limited: key financial ratios
Table 289: Lupin Limited: key facts
Table 290: Lupin Limited: key financials ($)
Table 291: Lupin Limited: key financials (Rs.)
Table 292: Lupin Limited: key financial ratios
Table 293: PT Kalbe Farma Tbk: key facts
Table 294: PT Kalbe Farma Tbk: key financials ($)
Table 295: PT Kalbe Farma Tbk: key financials (IDR)
Table 296: PT Kalbe Farma Tbk: key financial ratios
Table 297: PT Indofarma (Persero), Tbk: key facts
Table 298: PT Indofarma (Persero), Tbk: key financials ($)
Table 299: PT Indofarma (Persero), Tbk: key financials (IDR)
Table 300: PT Indofarma (Persero), Tbk: key financial ratios
Table 301: PT Sanbe Farma: key facts
Table 302: PT Soho Global Health: key facts
Table 303: Daiichi Sankyo Co., Ltd.: key facts
Table 304: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 305: Daiichi Sankyo Co., Ltd.: key financials (¥)
Table 306: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 307: Sawai Pharmaceutical Co., Ltd.: key facts
Table 308: Sawai Pharmaceutical Co., Ltd.: key financials ($)
Table 309: Sawai Pharmaceutical Co., Ltd.: key financials (¥)
Table 310: Sawai Pharmaceutical Co., Ltd.: key financial ratios
Table 311: Abbott Laboratories: key facts
Table 312: Abbott Laboratories: key financials ($)
Table 313: Abbott Laboratories: key financial ratios
Table 314: Krka, d. d., Novo mesto: key facts
Table 315: Krka, d. d., Novo mesto: key financials ($)
Table 316: Krka, d. d., Novo mesto: key financials (€)
Table 317: Krka, d. d., Novo mesto: key financial ratios
Table 318: Adcock Ingram Holdings Limited: key facts
Table 319: Adcock Ingram Holdings Limited: key financials ($)
Table 320: Adcock Ingram Holdings Limited: key financials (ZAR)
Table 321: Adcock Ingram Holdings Limited: key financial ratios
Table 322: Yuhan Corporation: key facts
Table 323: Yuhan Corporation: key financials ($)
Table 324: Yuhan Corporation: key financials (KRW)
Table 325: Yuhan Corporation: key financial ratios
Table 326: Esteve Group: key facts
Table 327: Abdi Ibrahim Ilac Sanayi ve Ticaret AS: key facts
Table 328: DEVA Holding: key facts
Table 329: DEVA Holding: key financials ($)
Table 330: DEVA Holding: key financials (TL)
Table 331: DEVA Holding: key financial ratios
Table 332: Nobel Pharmaceuticals: key facts

List of Figures
Figure 1: Global generics market value: $ billion, 2012–16
Figure 2: Global generics market volume: % of total pharma volume, 2012–16
Figure 3: Global generics market geography segmentation: % share, by value, 2016
Figure 4: Global generics market value forecast: $ billion, 2016–21
Figure 5: Global generics market volume forecast: % of total pharma volume, 2016–21
Figure 6: Forces driving competition in the global generics market, 2016
Figure 7: Drivers of buyer power in the global generics market, 2016
Figure 8: Drivers of supplier power in the global generics market, 2016
Figure 9: Factors influencing the likelihood of new entrants in the global generics market, 2016
Figure 10: Factors influencing the threat of substitutes in the global generics market, 2016
Figure 11: Drivers of degree of rivalry in the global generics market, 2016
Figure 12: Asia-Pacific generics market value: $ billion, 2012–16
Figure 13: Asia–Pacific generics market volume: % of total pharma volume, 2012–16
Figure 14: Asia–Pacific generics market geography segmentation: % share, by value, 2016
Figure 15: Asia-Pacific generics market value forecast: $ billion, 2016–21
Figure 16: Asia–Pacific generics market volume forecast: % of total pharma volume, 2016–21
Figure 17: Forces driving competition in the generics market in Asia-Pacific, 2016
Figure 18: Drivers of buyer power in the generics market in Asia-Pacific, 2016
Figure 19: Drivers of supplier power in the generics market in Asia-Pacific, 2016
Figure 20: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2016
Figure 21: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2016
Figure 22: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2016
Figure 23: Europe generics market value: $ billion, 2012–16
Figure 24: Europe generics market volume: % of total pharma volume, 2012–16
Figure 25: Europe generics market geography segmentation: % share, by value, 2016
Figure 26: Europe generics market value forecast: $ billion, 2016–21
Figure 27: Europe generics market volume forecast: % of total pharma volume, 2016–21
Figure 28: Forces driving competition in the generics market in Europe, 2016
Figure 29: Drivers of buyer power in the generics market in Europe, 2016
Figure 30: Drivers of supplier power in the generics market in Europe, 2016
Figure 31: Factors influencing the likelihood of new entrants in the generics market in Europe, 2016
Figure 32: Factors influencing the threat of substitutes in the generics market in Europe, 2016
Figure 33: Drivers of degree of rivalry in the generics market in Europe, 2016
Figure 34: France generics market value: $ billion, 2012–16
Figure 35: France generics market volume: % of total pharma volume, 2012–16
Figure 36: France generics market geography segmentation: % share, by value, 2016
Figure 37: France generics market value forecast: $ billion, 2016–21
Figure 38: France generics market volume forecast: % of total pharma volume, 2016–21
Figure 39: Forces driving competition in the generics market in France, 2016
Figure 40: Drivers of buyer power in the generics market in France, 2016
Figure 41: Drivers of supplier power in the generics market in France, 2016
Figure 42: Factors influencing the likelihood of new entrants in the generics market in France, 2016
Figure 43: Factors influencing the threat of substitutes in the generics market in France, 2016
Figure 44: Drivers of degree of rivalry in the generics market in France, 2016
Figure 45: Germany generics market value: $ billion, 2012–16
Figure 46: Germany generics market volume: % of total pharma volume, 2012–16
Figure 47: Germany generics market geography segmentation: % share, by value, 2016
Figure 48: Germany generics market value forecast: $ billion, 2016–21
Figure 49: Germany generics market volume forecast: % of total pharma volume, 2016–21
Figure 50: Forces driving competition in the generics market in Germany, 2016
Figure 51: Drivers of buyer power in the generics market in Germany, 2016
Figure 52: Drivers of supplier power in the generics market in Germany, 2016
Figure 53: Factors influencing the likelihood of new entrants in the generics market in Germany, 2016
Figure 54: Factors influencing the threat of substitutes in the generics market in Germany, 2016
Figure 55: Drivers of degree of rivalry in the generics market in Germany, 2016
Figure 56: Australia generics market value: $ billion, 2012–16
Figure 57: Australia generics market volume: % of total pharma volume, 2012–16
Figure 58: Australia generics market geography segmentation: % share, by value, 2016
Figure 59: Australia generics market value forecast: $ billion, 2016–21
Figure 60: Australia generics market volume forecast: % of total pharma volume, 2016–21
Figure 61: Forces driving competition in the generics market in Australia, 2016
Figure 62: Drivers of buyer power in the generics market in Australia, 2016
Figure 63: Drivers of supplier power in the generics market in Australia, 2016
Figure 64: Factors influencing the likelihood of new entrants in the generics market in Australia, 2016
Figure 65: Factors influencing the threat of substitutes in the generics market in Australia, 2016
Figure 66: Drivers of degree of rivalry in the generics market in Australia, 2016
Figure 67: Brazil generics market value: $ billion, 2012–16
Figure 68: Brazil generics market volume: % of total pharma volume, 2012–16
Figure 69: Brazil generics market geography segmentation: % share, by value, 2016
Figure 70: Brazil generics market value forecast: $ billion, 2016–21
Figure 71: Brazil generics market volume forecast: % of total pharma volume, 2016–21
Figure 72: Forces driving competition in the generics market in Brazil, 2016
Figure 73: Drivers of buyer power in the generics market in Brazil, 2016
Figure 74: Drivers of supplier power in the generics market in Brazil, 2016
Figure 75: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2016
Figure 76: Factors influencing the threat of substitutes in the generics market in Brazil, 201